Table 3.
Planar imaging/SPECT - Number (N) of hospitals/devices, data for examination protocols and collected patient data.
| Examination type | N hospitals/devices | Prescribed activities in the examination protocols mean/median |
Reported injected activities from the collected patient data |
||||||
|---|---|---|---|---|---|---|---|---|---|
| for protocols with a defined total activity [MBq] | for protocols with a weight based prescription [MBq/kg] | Number of reported datasets | Weight mean [kg] | Injected activity mean & SD [MBq] | Injected activity median [MBq] | Injected activity 3rd quartile [MBq] | Injected activity Min-max [MBq] | ||
| Brain imaging: I-123 benzamide beta-CIT | 21/28 | 177/185 | 2.4/2.4 | 222 | 78 | 181 ± 19 | 185 | 187 | 129-230 |
| Salivary gland scan: Tc-99m pertechnetate | 14/20 | 137/111 | 2.6/2.6 | 135 | 71 | 162 ± 75 | 157 | 186 | 71-434 |
| Thyroid imaging: Tc-99m pertechnetate | 29/38 | 73/74 | 1.0/1.0 | 321 | 75 | 76 ± 16 | 76 | 85 | 37-122 |
| Thyroid whole-body imaging: I-131 sodium iodide | 15/19 | 194/185 | - | 132 | 76 | 178 ± 89 | 185 | 186 | 74-371 |
| Parathyroid imaging: Tc-99m isonitrile | 22/34 | 470/400 | 4.9/4.9 | 249 | 76 | 465 ± 135 | 400 | 578 | 302-768 |
| Myocardial perfusion imaging: Tc-99m isonitrile 1-day protocol (rest and stress) | 20/23 | total: 1090/1050 | total: 12.75/12.75 | 180 | 81 | 1108 ± 165 | 1084 | 1141 | 731-1884 |
| Myocardial perfusion imaging: Tc-99m isonitrile 2-day protocol (rest and stress) | 4/5 | 595/550 per day | 4/4 | 30 | 80 | total: 1085 ± 376 | total: 1000 | 1558 | 509-1585 |
| Myocardial perfusion/vitality imaging: TI-201 chloride | 7/9 | 103/100 | 3.0/3.0 | 80 | 79 | 129 ± 88 | 100 | 111 | 64-376 |
| Lung perfusion imaging: Tc-99m macroaggregates | 29/42 | 129/125 | 1/1 | 345 | 79 | 128 ± 39 | 126 | 150 | 21-387 |
| Gastric imaging: Tc-99m marked chyme | 15/21 | 49/40 | 0.5/0.5 | 165 | 71 | 51 ± 29 | 41 | 55 | 10-165 |
| Renal imaging: Tc-99m MAG3/EC | 29/43 | 103/100 | 1.2/1 | 331 | 75 | 101 ± 30 | 98 | 110 | 57-205 |
| Renal imaging: Tc-99m DMSA | 17/23 | 110/100 | 1.4/1.4 | 110 | 73 | 109 ± 37 | 98 | 109 | 59-185 |
| Renal imaging: Tc-99m DTPA | 2/4 | 170/170 | - | 20 | 78 | 222 ± 15 | 223 | 232 | 176-247 |
| Adrenal imaging: I-123 MIBG | 7/9 | 302/300 | - | 42 | 81 | 288 ± 106 | 260 | 370 | 185-450 |
| Bleeding: Tc-99m pertechnetate, erythrocytes | 9/16 | 625/600 | 8.1/8.1 | 116 | 71 | 565 ± 73 | 556 | 597 | 400-808 |
| Inflammation imaging: Tc-99m anti-granulocytes antibodies | 13/15 | 661/700 | - | 104 | 81 | 688 ± 121 | 700 | 757 | 408-925 |
| SNL lymphoscintigraphy: Tc-99m colloid – 1-day protocol | 23/37 | 89/94 | - | 284 | 74 | 123 ± 138 | 98 | 138 | 21-781 |
| SNL lymphoscintigraphy: Tc-99m colloid – 2-day protocol | 5/8 | 94/110 | - | 62 | 74 | 119 ± 53 | 136 | 160 | 22-219 |
| Bone imaging: Tc-99m bisphosphonate | 29/50 | 627/650 | 8.9/9.1 | 424 | 77 | 652 ± 102 | 663 | 727 | 402-985 |
| Tumour/inflammation/receptor imaging: In-111 somatostatin receptor antagonist | 3/6 | 173/185 | 2.2/2.2 | 60 | 73 | 172 ± 32 | 160 | 199 | 118-257 |
| Tumour/inflammation/receptor imaging: Tc-99m somatostatin receptor antagonist | 8/10 | 731/740 | - | 79 | 77 | 751 ± 61 | 740 | 759 | 525-911 |
| Tumour/inflammation/receptor imaging: Tc-99m PSMA | 3/3 | 618/600 | - | 14 | 87 | 635 ± 57 | 607 | 661 | 587-786 |